When was Life Length founded?

Life Length was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Where is Life Length located?

Life Length is headquartered in Madrid, Spain.

Who is the current CEO of Life Length?

Stephen J Matlin of Life Length. They have also founded 1 company.

How many employees does Life Length have?

As of Jul 31, 2026, the latest employee count at Life Length is 40.

Is Life Length a funded company?

Life Length is a funded company, having raised a total of $2.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 01, 2015.

When was the latest funding round of Life Length?

Life Length's latest funding was a $***** Grant (prize money) round on Jan 11, 2024, with participation from 1 investor. Its primary sector is Oncology. In Spain, the Oncology sector has seen $215M in funding in 2026 to date.

Where does Life Length rank among its competitors?

Life Length ranks 21st amongst 121 active competitors, of which 38 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Life Length?

Life Length's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Life Length - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provides telomere length analysis technology for diagnosis. The company offers its proprietary technology for telomerase length detection for the health and aging process. It offers its services to physicians, individuals, researchers, and corporations. The company is involved in the development of biomarkers and its flagship product ONCOCHECK for clinical validation of Telomere Associated Variables (TAVs) as cancer biomarkers by its TAT technology for prostate cancer.

Website: lifelength.com
Social
Email ID: *****@lifelength.com
Phone Number: +1 **********

Key Metrics

Founded Year

2010

Location

Madrid, Spain

Stage

Seed

Total Funding

$2.7M in 6 rounds

Latest Funding Round

Grant (prize money), Jan 11, 2024, $*****

Investors

EIC Fund & 2 more

Ranked

21^st among 121 active competitors

Employee Count

40 as on Jul 31, 2026

Similar Companies

Seer & 148 more

View Life Length's full profile

Life Length has raised a total funding of $2.7M over 6 rounds. Its first funding round was on Sep 01, 2015. Its latest funding round was a Grant (prize money) round on Jan 11, 2024 for $*****. 1 investor participated in its latest round. Life Length has 3 institutional investors.

Here is the list of recent funding rounds of Life Length:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 11, 2024	4741695	Grant (prize money)	2994532	3082586	8247867	8109711
Jul 08, 2019	1062831	Seed	8623545	3480907	7577411	8668695
Dec 31, 2018	1374825	Grant (prize money)	9677537	2514272	1747413	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Life Length's funding rounds and investors

The founders of Life Length is Stephen J Matlin. Stephen J Matlin is the CEO of Life Length.

Here are the details of Life Length's key team members:

Stephen J Matlin: Founder & CEO of Life Length.

View details of Life Length's Founder profiles and Board Members

Life Length's employee count trend

Life Length has 40 employees as of Jul 26. Here is Life Length's employee count trend over the years:

Uncover Life Length's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Life Length include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Life Length, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
8th	Proteomics International 2001, Perth (Australia), Public	Medical technology company at the forefront of predictive diagnostics and bio-analytical services	-	MTPConnect, NorthStar Impact	55/100
9th	Fountain Life 2019, Orlando (United States), Series B	AI-guided diagnostics and restorative therapeutics to help people detect life-threatening diseases	$51.9M	Eos Ventures, Longevity Vision Fund & 2 others	55/100
10th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	55/100
21st	Life Length 2010, Madrid (Spain), Seed	Provides telomere length analysis technology for diagnosis	$2.7M	EIC Fund, Europa & 1 others	45/100